This study is looking at how well a special type of imaging, called [18F]FMISO-PET with contrast-enhanced MRI, can monitor and predict the effects of immunotherapy in people with triple negative breast cancer (stages II-IV). Researchers want to see if this imaging can help understand how immunotherapy is working. You might be able to join if you are a woman between 18 and 75 years old, have biopsy-proven triple negative breast cancer (stage II-IV), and are planning to start immunotherapy. You must also have more than 50% PD-L1 (a protein on cancer cells) positive. This study will enroll 20 patients and will not change your treatment plan, which will be decided by your oncologist. The main goal is to measure certain values from the PET and MRI scans at the beginning of the study.

Study design

This is an interventional study with 20 participants. It is a parallel imaging study, meaning it runs alongside your regular treatment.

What's involved

You will have a pre-study visit for consent, vital signs, blood tests, and an MRI fit test. You will then have up to three imaging visits, with the first one before you start immunotherapy.

Compensation

Not stated in the trial record.

Follow-up

Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.